*In-license or other partnership with third party.
†Sierra Oncology, Inc., a GSK company.
ACVR1, bone morphogenetic protein receptor kinase activin A receptor, type I; BCMA, B-cell maturation antigen; CD, cluster of differentiation; JAK1/2, Janus kinase 1/2; MOA, mechanism of action; MOD, mechanism of disease; NY‑ESO‑1, New York esophageal squamous cell carcinoma 1; PARP, poly ADP ribose polymerase; PD‑1, programmed cell death protein 1; PVRIG, poliovirus receptor–related immunoglobulin; TCR, T‑cell receptor; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; TIM-3, T-cell immunoglobulin and mucin domain-3.